Browsing Tag
Idiopathic pulmonary fibrosis
23 posts
Can LTI-03 break through in a crowded idiopathic pulmonary fibrosis market
Rein Therapeutics advances LTI-03 in Phase 2 IPF trials. Find out what this means for competition, execution risk, and future differentiation.
Why is Avalyn Pharma going public now, and what does it reveal about biotech risk appetite?
Avalyn Pharma has filed for a U.S. IPO to fund inhaled pulmonary fibrosis drugs. Read what the move signals for biotech markets and lung disease therapy.
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Avalyn Pharma advances AP02 into Phase 2 trials, testing inhaled drug delivery as a safer IPF strategy. Discover what this means for the fibrosis market.
United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
United Therapeutics reports strong Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis. Discover why this inhaled therapy could reshape treatment.
Contineum Therapeutics (NASDAQ: CTNM) shares slump after PIPE-307 fails to show efficacy in multiple sclerosis trial
PIPE-307 failed to meet efficacy endpoints in RRMS Phase 2, sending Contineum Therapeutics stock lower. Find out what’s next for PIPE-791 and MDD.
FDA lifts hold on Rein Therapeutics’ LTI-03 trial, reviving hopes for idiopathic pulmonary fibrosis treatment
FDA clears Rein Therapeutics to restart its Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, restoring investor confidence and trial momentum.
Can Calluna Pharma’s CAL101 finally change the game for idiopathic pulmonary fibrosis patients?
Calluna Pharma begins Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis, targeting S100A4 for a novel antifibrotic approach.
Trevi Therapeutics announces positive results for Haduvio in Phase 2b CORAL study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported a positive outcome from the planned sample size re-estimation…
Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP)…